白血球分离术市场 - 全球产业规模、份额、趋势、机会及预测（按类型、应用、最终用户、地区和竞争格局划分，2021-2031年）

全球白血球分离术市场预计将从 2025 年的 8,349 万美元成长到 2031 年的 1.1427 亿美元，复合年增长率为 5.37%。

白血球分离术是一种特殊的医疗程序，透过该程序将白血球从血液样本中分离出来，并将剩余成分输回患者的循环系统。市场成长的主要驱动因素是：由于血液系统骨髓恶性肿瘤分离术的需求不断增加，以控制白血球计数升高；此外，细胞免疫疗法研究的扩展也需要高品质的白血球包用于先进的治疗药物生产。近期统计数据凸显了这种临床紧迫性：根据美国癌症协会预测，2024年美国预计将新增约62,770例白血病病例，这凸显了高效细胞分离技术对于支持持续治疗和监测通讯协定的重要性。

儘管成长要素强劲，但由于血液分离设备和手术成本高昂，市场仍面临许多障碍。自动化设备所需的高额资本投入，加上一次性试剂盒的持续成本，限制了小规模医疗机构的普及，也阻碍了成本敏感型发展中地区的推广应用。这些经济限制有效地限制了这些关键技术的广泛应用，并阻碍了小规模医疗机构购置服务患者群体所需的必要基础设施。

市场驱动因素

CAR-T细胞疗法的快速商业化已成为全球白血球分离术市场的主要催化剂，显着提高了自体T细胞采集的分离系统使用率。随着监管机构将这些治疗方法的核准扩大到更早的治疗方案，生产网络面临着快速扩大规模以应对更大患者数量的压力，这就需要建立更密集的、具备分离术能力的采集中心基础设施。这种商业性动能也体现在依赖这些流程的关键市场产品的财务成功上。根据强生公司2024年10月发布的2024年第三季财报，其用于治疗多发性骨髓瘤的CAR-T疗法Carvykti的全球营业销售额达到2.86亿美元，年增87.6%。如此快速的收入成长表明患者可及性不断提高，并且与生产这些个人化疗法所需的采集流程数量增加直接相关，从而推动了市场扩张。

同时，免疫肿瘤学和细胞疗法临床试验的激增显着提高了对临床治疗和用于製程开发的研究级白血球包装的需求。研发人员依赖可靠的高品质细胞材料供应，以检验生产流程并对新候选药物进行安全性测试，从而确保血球分离术提供者的持续收入来源。根据美国基因与细胞治疗学会于2024年4月发布的《2024年第一季基因、细胞和RNA疗法趋势报告》，全球在开发平臺基因、细胞和RNA治疗方法已扩展至4021种，涵盖从临床前到註册前的各个阶段。这项大规模的研究工作得到了联邦政府的大力支持，包括美国国家癌症研究所2024财年72.2亿美元的营运预算，这些资金有助于稳定供应链，并确保临床和实验室环境中对白血球分离技术的稳定需求。

市场挑战

白血球分离设备和营运成本带来的沉重经济负担是市场扩张的主要障碍。自动化血球分离设备需要高额的资本投入，因此只有资金雄厚的大型医疗中心和核心实验室才能负担得起。这项经济门槛使得小规模的医疗机构和社区诊所，尤其是在对成本高度敏感的发展中地区，难以获得这项关键技术，从而限制了设备的安装数量和可服务的患者数量。

除了初始设备购置成本外，市场还面临来自一次性试剂盒和维护成本持续上涨的压力。这些营运费用直接影响手术的成本效益和血液製品的最终价格。近期产业数据也印证了这个成本上涨趋势。根据美国血液和生物治疗促进协会 (AABB) 发布的《2025 年全国血液采集和利用调查报告》，医院购买单采血小板的平均价格较上一报告週期上涨了 65 美元/单位。单采血小板成分成本的上涨给医疗机构带来了沉重的经济负担，最终迫使他们限制治疗量，并阻碍了依赖白血球分离术的治疗方法的广泛应用。

市场趋势

携带式和移动式白血球分离设备的兴起，透过分散获取关键细胞材料的途径，从根本上改变了市场格局。自主型行动采血中心的引进，克服了过去阻碍偏远和医疗资源匮乏地区捐血者参与的后勤障碍。这种转变使得在社区内直接收集高品质的白血球分离包成为可能，减轻了患者前往固定中心的负担。近期旨在扩大细胞治疗供应链地理覆盖范围的基础建设，正是此一趋势的体现。根据BioBridge Global在2025年5月发布的新闻稿，该公司宣布运作首个移动式白血球分离中心，该中心旨在为超过63,000平方英里的区域提供医疗服务，显着扩大免疫细胞采集的覆盖范围。

同时，封闭式自动化处理平台的引进正在影响市场，这要求上游工程必须与无菌生产流程相容。随着细胞疗法开发商从手动开放式实验室操作转向全自动生态系统，对能够与下游生物反应器无缝整合以最大限度降低污染风险和人事费用的白血球分离产品的需求日益增长。这种向自动化的转变确保了细胞材料在整个静脉到静脉流程的活性和一致性。近期的行业合作已证实了此类整合系统的有效性。Terumo Corporation血液与细胞技术公司和芝加哥大学于2025年11月宣布，研究人员使用Quantum Flex平台在10天内成功将1000万个外周血单核细胞（PBMC）扩增至90亿个，证明了有效整合采集和处理技术所能实现的扩充性。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球白血球分离术市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依类型（白血球去除设备、血球分离设备、白血球去除柱、细胞分离器、白血球去除过滤器、白血球去除耗材）
  • 依用途（研究用途、治疗用途）
  • 按最终用户划分（血液成分供应商和血液中心、学术研究机构、製药和生物技术公司、医院、输血中心）
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章 北美白血球分离术市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲白血球分离术市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区白血球分离术市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲白血球分离术市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章 南美白血球分离术市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球白血球分离术市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Asahi Kasei Medical Co. Ltd
• Haemonetics Corporation
• TERUMO BCT INC.
• STEMCELL Technologies Canada Inc.
• Fresenius SE & Co. KGaA
• B. Braun SE
• Caltag Medsystems Limited
• Precision Medicine Group, LLC
• LMB Technologie GmbH
• Grifols, SA
• Kaneka Pharma Europe NV

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Leukapheresis Market is projected to expand from USD 83.49 Million in 2025 to USD 114.27 Million by 2031, registering a CAGR of 5.37%. Leukapheresis is a specialized medical procedure wherein white blood cells are separated from drawn blood, while the remaining components are returned to the patient's circulation. Market growth is primarily driven by the increasing prevalence of hematological malignancies, which fuels the demand for therapeutic apheresis to manage elevated white blood cell counts, and the expansion of cell-based immunotherapy research necessitating high-quality leukopaks for the manufacturing of Advanced Therapy Medicinal Products. This clinical urgency is highlighted by recent statistics; according to the American Cancer Society, approximately 62,770 new cases of leukemia were projected to be diagnosed in the United States in 2024, underscoring the critical need for efficient cellular separation technologies to support ongoing treatment and research protocols.

Despite these robust growth drivers, the market faces a significant hurdle due to the substantial costs associated with apheresis equipment and procedures. The high capital expenditure required for automated devices, combined with the recurring expenses for disposable kits, limits accessibility for smaller healthcare facilities and creates barriers to adoption in cost-sensitive developing regions. These financial constraints effectively restrict the widespread implementation of these essential technologies, preventing smaller institutions from acquiring the necessary infrastructure to serve their patient populations.

Market Driver

The rapid commercialization of CAR-T cell therapies acts as a primary catalyst for the global leukapheresis market, significantly increasing the utilization of apheresis systems for harvesting autologous T-cells. As regulatory bodies extend approvals for these treatments to earlier lines of therapy, manufacturing networks are compelled to scale rapidly to handle larger patient volumes, necessitating a denser infrastructure of collection centers capable of performing apheresis. This commercial momentum is reflected in the financial success of key market products dependent on these procedures; according to Johnson & Johnson's 'Q3 2024 Earnings Report' from October 2024, worldwide operational sales for Carvykti, a CAR-T therapy for multiple myeloma, rose by 87.6% year-over-year to $286 million. Such swift revenue growth indicates broadened patient access and directly correlates with a higher number of collection procedures needed to produce these personalized treatments, thereby fueling market expansion.

Concurrently, a surge in immuno-oncology and cell therapy clinical trials is substantially boosting the demand for both clinical procedures and research-grade leukopaks used in process development. Developers depend on consistent access to high-quality cellular starting materials to validate manufacturing processes and conduct safety studies for new candidates, ensuring a continuous revenue stream for apheresis providers. According to the American Society of Gene + Cell Therapy's 'Gene, Cell, + RNA Therapy Landscape Q1 2024 Quarterly Report' released in April 2024, the global pipeline has grown to include 4,021 gene, cell, and RNA therapies in development, spanning from preclinical to pre-registration stages. This extensive research activity is supported by significant federal investment, such as the National Cancer Institute's 2024 operating budget of $7.22 billion, which helps stabilize the supply chain and ensures a steady requirement for leukapheresis technologies in both clinical and laboratory settings.

Market Challenge

The significant financial burden associated with leukapheresis equipment and operational expenses serves as a major obstacle to broader market growth. Automated apheresis devices require a high capital expenditure, effectively limiting their acquisition to large, well-funded medical centers and reference laboratories. This financial threshold prevents smaller healthcare facilities and community clinics, particularly in cost-sensitive developing regions, from adopting these essential technologies, thereby restricting the overall installed base and limiting the volume of patients who can access these services.

In addition to the initial asset purchase, the market faces sustained pressure from rising recurring costs related to disposable kits and maintenance. These operational expenses directly impact the affordability of procedures and the final cost of blood products. This upward cost trajectory is confirmed by recent industry data; according to the Association for the Advancement of Blood & Biotherapies (AABB) in 2025, findings from the National Blood Collection and Utilization Survey indicated that the median price hospitals paid for apheresis-derived platelets increased by $65 per unit compared to the previous reporting cycle. Such escalating costs for apheresis-derived components place an economic strain on healthcare providers, ultimately forcing them to limit procedure volumes and hindering the widespread scalability of leukapheresis-dependent therapies.

Market Trends

The rise of portable and mobile leukapheresis units is fundamentally reshaping the market by decentralizing access to essential cellular starting materials. By deploying self-contained, mobile collection centers, providers can circumvent logistical barriers that historically restricted donor participation in remote or underserved areas. This shift enables the collection of high-quality leukopaks directly within communities, reducing the burden on patients who previously had to travel to fixed-site reference centers. This trend is illustrated by recent infrastructure developments aimed at extending the geographic reach of cell therapy supply chains; according to BioBridge Global's May 2025 press release regarding the launch of their first mobile leukapheresis center, the new unit is designed to support healthcare services across a region exceeding 63,000 square miles, significantly expanding the catchment area for immune cell collection.

Simultaneously, the adoption of closed-system automated processing platforms is influencing the market by necessitating upstream compatibility with sterile manufacturing workflows. As cell therapy developers transition from manual, open-lab procedures to fully automated ecosystems, there is a heightened requirement for leukapheresis products that integrate seamlessly with downstream bioreactors to minimize contamination risks and labor costs. This move towards automation ensures that the cellular starting material retains viability and consistency throughout the vein-to-vein process. The efficacy of such integrated systems is demonstrated by recent industry collaborations; according to a November 2025 announcement by Terumo Blood and Cell Technologies and the University of Chicago, researchers successfully expanded 10 million PBMCs to 9 billion cells in 10 days using the Quantum Flex platform, proving the scalability achievable when collection and processing technologies are effectively aligned.

Key Market Players

• Asahi Kasei Medical Co. Ltd
• Haemonetics Corporation
• TERUMO BCT INC.
• STEMCELL Technologies Canada Inc.
• Fresenius SE & Co. KGaA
• B. Braun SE
• Caltag Medsystems Limited
• Precision Medicine Group, LLC
• LMB Technologie GmbH
• Grifols, S.A.
• Kaneka Pharma Europe NV

Report Scope

In this report, the Global Leukapheresis Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Leukapheresis Market, By Type

• Leukapheresis Devices
• Apheresis Devices
• Leukapheresis Columns
• Cell Separators
• Leukoreduction Filters
• Leukapheresis Disposables

Leukapheresis Market, By Application

• Research Applications
• Therapeutic Applications

Leukapheresis Market, By End User

• Blood Component Providers and Blood Centers
• Academic and Research Institutes
• Pharmaceutical and Biotechnology Companies
• Hospitals
• Transfusion Centers

Leukapheresis Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Leukapheresis Market.

Available Customizations:

Global Leukapheresis Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Leukapheresis Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Leukapheresis Devices, Apheresis Devices, Leukapheresis Columns, Cell Separators, Leukoreduction Filters, Leukapheresis Disposables)
  • 5.2.2. By Application (Research Applications, Therapeutic Applications)
  • 5.2.3. By End User (Blood Component Providers and Blood Centers, Academic and Research Institutes, Pharmaceutical and Biotechnology Companies, Hospitals, Transfusion Centers)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Leukapheresis Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Application
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Leukapheresis Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By End User
  • 6.3.2. Canada Leukapheresis Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By End User
  • 6.3.3. Mexico Leukapheresis Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By End User

7. Europe Leukapheresis Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Application
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Leukapheresis Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By End User
  • 7.3.2. France Leukapheresis Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By End User
  • 7.3.3. United Kingdom Leukapheresis Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy Leukapheresis Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain Leukapheresis Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By End User

8. Asia Pacific Leukapheresis Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Application
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Leukapheresis Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By End User
  • 8.3.2. India Leukapheresis Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By End User
  • 8.3.3. Japan Leukapheresis Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By End User
  • 8.3.4. South Korea Leukapheresis Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia Leukapheresis Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By End User

9. Middle East & Africa Leukapheresis Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Application
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Leukapheresis Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By End User
  • 9.3.2. UAE Leukapheresis Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By End User
  • 9.3.3. South Africa Leukapheresis Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By End User

10. South America Leukapheresis Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Application
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Leukapheresis Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By End User
  • 10.3.2. Colombia Leukapheresis Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By End User
  • 10.3.3. Argentina Leukapheresis Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Leukapheresis Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Asahi Kasei Medical Co. Ltd
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Haemonetics Corporation
• 15.3. TERUMO BCT INC.
• 15.4. STEMCELL Technologies Canada Inc.
• 15.5. Fresenius SE & Co. KGaA
• 15.6. B. Braun SE
• 15.7. Caltag Medsystems Limited
• 15.8. Precision Medicine Group, LLC
• 15.9. LMB Technologie GmbH
• 15.10. Grifols, S.A.
• 15.11. Kaneka Pharma Europe NV

16. Strategic Recommendations

17. About Us & Disclaimer